US-based HSRx Biopharmaceutical has reported positive results from studies testing the efficacy of HSRx 431 against Zika virus.

HSRx 431 has been developed as an orally administered, broad-spectrum, antiviral drug candidate.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The screening studies conducted by SRI International in their Shenandoah Valley facilities, validated the efficacy of HSRx 431 in combating the Zika virus.

The virus is primarily transmitted by Aedes mosquitoes, triggering symptoms such as mild fever, skin rash, conjunctivitis, muscle and joint pain, malaise, or headache.

HSRx CEO Thomas Sullivan Jr said: "We patented HSRx 431 alone and in combination with Oseltamivir (Tamiflu) and other antivirals, enabling it to become the broad spectrum antiviral drug of choice for the early treatment and prevention of a wide variety of viral infections, including Zika, dengue, chikungunya and influenza, without the need to identify the causative agent.

“The CDC advises that millions of people are sickened, hundreds of thousands are hospitalised and tens of thousands of people die from flu every year in the US.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
"Combining HSRx 431 and Oseltamivir will produce a globally needed, orally-delivered, broad-spectrum antiviral drug with long shelf life and long patent life."

“Combining HSRx 431 and Oseltamivir will produce a globally needed, orally-delivered, broad-spectrum antiviral drug with long shelf life and long patent life."

The US National Institute of Allergy and Infectious Diseases (NIAID) director Anthony Fauci and NIAID senior scientific advisor David Morens suggested the urgency of the development of broad-spectrum antiviral drugs effective against a range of viruses instead of a one-bug-one-drug approach.

Previously conducted in vivo studies suggested the safety and efficacy of HSRx 431 against dengue and chikungunya infections.

The company is planning to start a human trial of HSRx 431 next year.

Image: Effectiveness data of HSRx 431 against Zika virus. Photo: courtesy of PRNewsFoto/HSRx Biopharmaceutical.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact